基于术前MRI影像组学预测乳腺癌复发并个体化辅助放疗决策的外部验证研究
研究基于771例来自两个独立中心的乳腺癌患者术前MRI构建影像组学签名Rad-score,训练集504例来自云南省肿瘤医院,外部测试集267例来自Duke乳腺癌MRI研究。高-risk组RFS显著更差(训练集p=0.001,测试集p=0.048),联合模型预测复发风险的AUC为0.752(95%CI 0.698-0.807)。辅助放疗在高-risk组与结局无关(训练集p=0.665,测试集p=0.903),而在低-risk组与RFS显著相关(训练集p=0.004,测试集P<0.001)。
要点
- Rad-score可有效预测乳腺癌预后并识别不能从辅助放疗获益的高-risk患者。
- 联合模型预测复发风险AUC为0.752(95%CI 0.698-0.807)。
- 低-risk组辅助放疗与RFS显著相关,高-risk组辅助放疗与结局无关。
核心结论
- Rad-score可有效预测乳腺癌患者预后,并识别不能从辅助放疗获益的高-risk患者。
研究设计与样本
- 研究纳入两个独立中心共771例 eligible 乳腺癌患者,训练集504例来自云南省肿瘤医院,外部测试集267例来自Duke乳腺癌MRI研究。
- 采用Pearson相关分析和聚类构建影像组学签名Rad-score,按最佳截断值将患者分为高-risk组和低-risk组并评估预后价值。
- 基于影像组学特征结合独立临床病理危险因素开发联合模型列线图,并从区分度、校准和临床实用性评估联合模型性能。
- 采用Kaplan-Meier分析识别从辅助放疗中获益的患者。
主要发现
- 高-risk组在训练集和测试集中均与更差的RFS显著相关(p=0.001和0.048)。
- 联合模型可准确预测乳腺癌复发风险(AUC 0.752;95%CI 0.698-0.807)。
- 辅助放疗与高-risk患者结局无关(训练集和测试集:p=0.665和0.903)。
- 在低-risk组中,辅助放疗与RFS显著相关(训练集和测试集:p=0.004和P<0.001)。
关键数值与推荐
- 按最佳截断值将患者分为高-risk组和低-risk组。
- 联合模型预测复发风险的AUC为0.752(95%CI 0.698-0.807)。
- 高-risk组与更差RFS相关:训练集p=0.001,测试集p=0.048。
- 辅助放疗与高-risk患者结局无关:训练集p=0.665,测试集p=0.903。
- 低-risk组辅助放疗与RFS显著相关:训练集p=0.004,测试集P<0.001。
临床怎么用
- 可利用术前MRI影像组学Rad-score对乳腺癌患者进行复发风险分层。
- 对Rad-score识别的高-risk患者,辅助放疗未显示与结局相关,决策时需综合评估。
- 对低-risk组患者,辅助放疗与RFS显著相关,可考虑作为放疗获益人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To develop a radiomics signature based on preoperative MRI to predict recurrence-free survival (RFS) and which patients will benefit from adjuvant radiotherapy in breast cancer patients. EXPERIMENTAL DESIGN: 771 eligible patients from two independent centers were collected. The training set (n = 504) obtained was from the Yunnan Cancer Hospital, and the external test set (n = 267) was obtained from the Duke Breast Cancer MRI Study. Pearson correlation analysis and clustering were used to construct the radiomics signature Rad-score. Based on the best cut-off value, the patients were divided into a high-risk group and a low-risk group, and the prognostic value was evaluated. A combined model nomogram was developed based on the radiomics features incorporating independent clinicopathological risk factors. The combined model's performance was assessed regarding its discrimination, calibration, and clinical usefulness. Kaplan-Meier analysis was used to identify patients who benefited from adjuvant radiotherapy. RESULTS: The high-risk group was significantly associated with worse RFS in the training and test sets (p = 0.001 and 0.048). The combination model can accurately predict BC recurrence risk (AUC, 0.752; 95% confidence interval [CI], 0.698-0.807). Additionally, adjuvant radiotherapy was not associated with the outcome of high-risk patients (training and test sets: p = 0.665 and 0.903, respectively). In the low-risk group, adjuvant radiotherapy was significantly associated with RFS (training and test sets: p = 0.004 and P<0.001). CONCLUSIONS: The Rad-score can effectively predict the prognosis of patients with breast cancer, and identify high-risk patients who do not benefit from adjuvant radiotherapy. CLINICAL TRIAL NUMBER: Not applicable.
引用
- Long M, Xie Y, Ruan J, et al. Personalizing adjuvant radiotherapy decisions in breast cancer: an externally test MRI radiomics approach for recurrence risk stratification. Radiat Oncol. 2026. PMID: 42251357. doi:10.1186/s13014-026-02868-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。